Challenges	0	9
in	11	12
the	14	16
control	18	24
of	26	27
gonorrhea	29	37
in	39	40
South	42	46
America	48	54
and	56	58
the	60	62
Caribbean	64	72
:	73	73
monitoring	75	84
the	86	88
development	90	100
of	102	103
resistance	105	114
to	116	117
antibiotics	119	129
.	130	130

:	132	132
The	134	136
objective	138	146
of	148	149
this	151	154
study	156	160
was	162	164
to	166	167
ascertain	169	177
the	179	181
antimicrobial	183	195
susceptibility	197	210
of	212	213
Neisseria	215	223
gonorrhoeae	225	235
isolates	237	244
from	246	249
6	251	251
South	253	257
American	259	266
and	268	270
13	272	273
Caribbean	275	283
countries	285	293
participating	295	307
in	309	310
the	312	314
Gonococcal	316	325
Antimicrobial	327	339
Surveillance	341	352
Program	354	360
(	362	362
GASP	363	366
)	367	367
from	369	372
1990	374	377
to	379	380
1999	382	385
.	386	386

:	388	388
A	390	390
GASP	392	395
network	397	403
of	405	406
laboratories	408	419
was	421	423
launched	425	432
in	434	435
the	437	439
Americas	441	448
and	450	452
the	454	456
Caribbean	458	466
during	468	473
the	475	477
1990s	479	483
.	484	484

Standardized	486	497
methods	499	505
and	507	509
interpretative	511	524
criteria	526	533
were	535	538
established	540	550
for	552	554
the	556	558
isolation	560	568
of	570	571
N	573	573
.	574	574
gonorrhoeae	576	586
,	587	587
strain	589	594
identification	596	609
,	610	610
and	612	614
determination	616	628
,	629	629
and	631	633
quality	635	641
control	643	649
of	651	652
antimicrobial	654	666
susceptibility	668	681
.	682	682

:	684	684
Two	686	688
countries	690	698
(	700	700
Argentina	701	709
and	711	713
Uruguay	715	721
)	722	722
maintained	724	733
continuous	735	744
surveillance	746	757
during	759	764
the	766	768
study	770	774
period	776	781
.	782	782

Some	784	787
countries	789	797
gathered	799	806
data	808	811
periodically	813	824
and	826	828
several	830	836
others	838	843
were	845	848
unable	850	855
to	857	858
initiate	860	867
antimicrobial	869	881
surveillance	883	894
as	896	897
a	899	899
result	901	906
of	908	909
lack	911	914
of	916	917
resources	919	927
.	928	928

The	930	932
percentage	934	943
of	945	946
penicillin	948	957
-	958	958
resistant	959	967
N	969	969
.	970	970
gonorrhoeae	972	982
isolated	984	991
in	993	994
the	996	998
region	1000	1005
over	1007	1010
the	1012	1014
decade	1016	1021
varied	1023	1028
considerably	1030	1041
(	1043	1043
1	1044	1044
.	1045	1045
0	1046	1046
-	1047	1047
11	1048	1049
.	1050	1050
9	1051	1051
%	1052	1052
carried	1054	1060
chromosomal	1062	1072
resistance	1074	1083
and	1085	1087
17	1089	1090
.	1091	1091
9	1092	1092
-	1093	1093
38	1094	1095
.	1096	1096
8	1097	1097
%	1098	1098
produced	1100	1107
beta	1109	1112
-	1113	1113
lactamase	1114	1122
)	1123	1123
with	1125	1128
an	1130	1131
overall	1133	1139
trend	1141	1145
to	1147	1148
declining	1150	1158
numbers	1160	1166
of	1168	1169
penicillin	1171	1180
-	1181	1181
resistant	1182	1190
isolates	1192	1199
.	1200	1200

For	1202	1204
tetracycline	1206	1217
,	1218	1218
7	1220	1220
.	1221	1221
4	1222	1222
%	1223	1223
to	1225	1226
36	1228	1229
.	1230	1230
3	1231	1231
%	1232	1232
carried	1234	1240
chromosomal	1242	1252
resistance	1254	1263
,	1264	1264
whereas	1266	1272
12	1274	1275
.	1276	1276
0	1277	1277
%	1278	1278
to	1280	1281
27	1283	1284
.	1285	1285
4	1286	1286
%	1287	1287
carried	1289	1295
plasmid	1297	1303
-	1304	1304
mediated	1305	1312
resistance	1314	1323
.	1324	1324

There	1326	1330
were	1332	1335
no	1337	1338
reports	1340	1346
of	1348	1349
ciprofloxacin	1351	1363
-	1364	1364
resistant	1365	1373
isolates	1375	1382
,	1383	1383
although	1385	1392
N	1394	1394
.	1395	1395
gonorrhoeae	1397	1407
with	1409	1412
decreased	1414	1422
susceptibility	1424	1437
to	1439	1440
ciprofloxacin	1442	1454
and	1456	1458
azithromycin	1460	1471
as	1473	1474
well	1476	1479
as	1481	1482
spectinomycin	1484	1496
-	1497	1497
resistant	1498	1506
isolates	1508	1515
were	1517	1520
identified	1522	1531
in	1533	1534
some	1536	1539
countries	1541	1549
.	1550	1550
